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Background: In Parkinson’s disease the degree of motor impairment can be classiﬁed with respect to
tremor dominant and akinetic rigid features. While tremor dominance and akinetic rigidity might
represent two ends of a continuum rather than discrete entities, it would be important to have non-
invasive markers of any biological differences between them in vivo, to assess disease trajectories and
response to treatment, as well as providing insights into the underlying mechanisms contributing to
heterogeneity within the Parkinson’s disease population.
Methods: Here, we used magnetic resonance imaging to examine whether Parkinson’s disease patients
exhibit structural changes within the basal ganglia that might relate to motor phenotype. Speciﬁcally, we
examined volumes of basal ganglia regions, as well as transverse relaxation rate (a putative marker of
iron load) and magnetization transfer saturation (considered to index structural integrity) within these
regions in 40 individuals.
Results: We found decreased volume and reduced magnetization transfer within the substantia nigra in
Parkinson’s disease patients compared to healthy controls. Importantly, there was a positive correlation
between tremulous motor phenotype and transverse relaxation rate (reﬂecting iron load) within the
putamen, caudate and thalamus.
Conclusions: Our ﬁndings suggest that akinetic rigid and tremor dominant symptoms of Parkinson’s
disease might be differentiated on the basis of the transverse relaxation rate within speciﬁc basal ganglia
structures. Moreover, they suggest that iron load within the basal ganglia makes an important contri-
bution to motor phenotype, a key prognostic indicator of disease progression in Parkinson’s disease.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Recent evidence suggests that motor-impairments in Parkin-
son’s disease (PD) can be classiﬁed on a continuum with tremor
dominant (TD) and akinetic rigid (AR) symptoms as extreme ends
[1]. However, the precise underlying differences in neural; fax: þ49 0 40 7410 59955.
r Ltd. Open access under CC BY license.pathology remain to be established. Physiologically, patients with
predominantly AR phenotype have higher levels of neuronal loss,
gliosis, extra-neuronal melanin deposits and neuro-axonal dystro-
phy in the SN compared to individuals with predominantly TD
phenotype [2]. Furthermore, AR symptoms are associated with
greater reductions in dopamine levels within the globus pallidus
[3], and higher levels of cortical Lewy bodies [4]. Nigro-striatal
degeneration in PD closely correlates with bradykinesia and rigid-
ity but, importantly, not with tremor [5].
Another pathological hallmark of PD is alteration of brain iron
level [6]. In particular, iron levels of the basal ganglia (BG),
including substantia nigra (SN), are increased in PD pointing
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meostasis [6]. Moreover, work in animals [7] raises the possibility of
a direct link between AR/TD motor symptoms and changes in iron
levels within the BG.
In vivo, structural changes can be quantiﬁed on the basis of MRI
measures such as R2* and magnetization transfer (MT) [8]. R2* is
sensitive to iron levels [9] and in the midbrain it correlates with
impaired motor performance [10]. MT, on the other hand, relates to
the exchange of magnetization between mobile water protons and
protons that are immobilized by macromolecules [11]. Although
MT changes can have several region-speciﬁc physiological causes,
within the SN of PD patients [12] and healthy older controls [13]MT
changes likely relate to neuronal loss and/or degradation of the
neuromelanin macromolecule scaffolding [14].
Here, we investigated the pathophysiology of PD and their
relationship with motor symptoms using MRI. We predicted higher
structural integrity (MT and/or size) of the BG in healthy controls
compared to PD patients, and a direct relationship between iron
content (R2*) and AR/TD motor symptoms. Finally, we investigated
the relationship between MT and R2* within these structures [6].
2. Methods
2.1. MRI acquisition
Whole-head quantitative MRI was performed on a 3-tesla whole body magnetic
resonance imaging scanner (Magnetom TIM Trio, Siemens). It comprised multi-
parameter mapping, which was based on multi-echo 3D FLASH (fast low angle
shot) acquisitions at a spatial resolution of 1 mm3 [8]. Brieﬂy, whole brain images
were acquiredwith predominant T1-, proton density, andMT-weighting imposed by
the choice of repetition time (TR) and ﬂip angle (T1-w: 18.7 ms/20; PD-w and MT-
w: 23.7 ms/6) and by applying an off-resonance Gaussian-shaped RF pulse (4 ms
duration, 220 nominal ﬂip angle, 2 kHz frequency offset) prior to non-selective
excitation for the MT-w acquisition, respectively. Alternating gradient echoes were
acquired at six equidistant echo times (TE) between 2.2 ms and 14.7 ms for the T1-
and MT-weighted acquisitions with two additional echoes at TE ¼ 17.2 ms andFig. 1. Regions of interest (ROI). The SN was deﬁned manually for each subject. All other ROI
overlaid on an individual T1-weighted image and lower row shows the subject’s MT-image19.7 ms for the proton density-weighted acquisition. These multiple TE images were
later averaged into one image for each weighting (e.g., T1-w, MT-w, PD-w) to in-
crease signal to noise ratio.
Each scanning sequence (MTw, T1w, and proton density-weighted) was rela-
tively short (only w7 min) which reduces possible within-scan motion. Between
scan motion was accounted for by co-registration of the acquired images. To keep
motion artifacts to a minimum, care was taken that each subject could rest on the
scanner bed in a comfortable position and cushion padding was used for head ﬁx-
ation. Therefore, motion artifacts were minimized, which was further corroborated
by visual inspection of the images.
2.2. Data processing and region of interest analysis
Data were reconstructed using SPM8 routines (www.ﬁl.ion.ucl.ac.uk/spm) and
Matlab tools (The Math-Works Inc.; Natick, MA, USA). For each subject, we calcu-
lated parameter maps of the MT saturation and the effective transverse relaxation
rate R2* [8]; the images for different modalities were co-registered using rigid-body
transformation. MT saturation can be regarded as a semi-quantitative measure,
which corresponds to the percentage loss of magnetization imposed by a single MT
pulse (in percent units e p.u). MT is implicitly corrected for differences in relaxation
times and excitation ﬂip angle, thus differing from the more commonly used MT
ratio, the percentage reduction of the steady state signal. We did not use MT-ratio
(MTR) since it is sensitive to non MT-speciﬁc effects such as changes in T1 or the
RF transmit ﬁeld inhomogeneities.
For each subject the following ‘Regions Of Interest’ (ROIs) were deﬁned from
native space (T1-image) using FreeSurfer (http://surfer.nmr.mgh.harvard.edu/):
pallidum, putamen, caudate, nucleus accumbens and (entire) thalamus. Further
subdivision of these structures was beyond the scope of this study. The thalamus
was included since it constitutes a major input/output region of the BG and thus is of
interest in the pathophysiology of PD. For each ROI we computed its volume, and
mean R2* and MT value (Table S1).
FreeSurfer does not support routines to automatically segment the SN. There-
fore, it was deﬁned manually for each subject on the basis of their MT-image (see
Fig. 1) by a rater who was blind with respect to the subject’s identity (C.E.). For a
subset of 14 images this procedure was performed twice. An Intraclass Correlation
Coefﬁcient agreement (ICC agreement) of 0.90 for the right and 0.91 for the left
hemisphere indicated high intra-rater reliability.
The SNwas segmented on the basis of MT images for three reasons. First, on MT-
images the SN can be distinguished from surrounding structures as a bright stripe
while the adjacent red nucleus and cerebral peduncle appear dark (Fig. 1); second,s were segmented automatically (see Methods). Upper row shows left hemisphere ROIs
.
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strated that MT parameter maps outperform T1-weighted images for SN segmen-
tation [15]. In fact, the advantage of MT maps in contrast to T1-w images is that they
are insensitive to iron susceptibility effects and thus mix fewer contrast compo-
nents. Moreover, SN segmentation using T2*-w images might suffer from the
problem that T2* contrast changes protrude beyond the structure with different
susceptibility (i.e. SN).
FreeSurfer is one of the most reliable tools for automated segmentation
currently available. Its morphometric procedures show good test-retest reliability
across scanner manufacturers and ﬁeld strengths [16]. Nevertheless, high accuracy
for each ROI was conﬁrmed by visual inspection. Rare cases of minor imprecision
were not manually corrected.
2.3. Group comparisons
To identify possible global brain atrophies, individual whole brain measures
were calculated for each modality (volume, MT and R2*) and compared using linear
mixed effects (LME)models. Moreover, for each ROI volume, MTand R2* values were
compared using LME models which included hemisphere as within factor. None of
the contrasts of interest showed a signiﬁcant interaction between diagnosis (PD vs.
controls) and hemisphere. Models on volumetric measures included intracranial
volume (ICV) as covariate of no interest to control for potential global brain atro-
phies. All statistical models included age as covariates of no interest to control for
possible age-related effects.
2.4. Regression analyses
We used linear regression analysis to investigate:
(1) the relationship between brain measures (R2* and MT) and motor symptoms
(i.e. subtype ratio; patients only),
(2) the correlation between MT and R2* values within each ROI (patients and
controls).
Each linear regression analysis included two steps which both resulted in a R2adj
value (adj abbreviates adjusted): ﬁrst, a model was computed including only one
variable of interest (e.g., MT) and the two covariates of no interest (age and ICV).
Next, the second variable of interest (e.g., R2*) was added to the model. The dif-
ference between both R2adj (i.e. DR
2
adj also known as ‘R
2
adj added’) corresponds to the
increase in explained variance by the second variable of interest [17]. Thus, it can be
regarded as effect size for the correlation between both variables of interest inde-
pendent of the variables of no interest (i.e. age, ICV). Note, that this type of linear
regression analysis does not provide r-values.
All statistical analyses were conducted using ‘R’ (R Development Core Team, 2007;
version 2.11.1). In the results section, the term ‘signiﬁcant’ relates to p-values <0.05.
Note that we report individual p-values uncorrected for multiple comparisons.
This approach is based on the suggestion that tests of a priori hypotheses (as in our
case, see Introduction) do not necessarily need a signiﬁcance level adjustment [18].
Instead, the number of observed signiﬁcant results (four in the group comparisons
and six in the regression analyses) exceed the number of probable random effects
(0.9 for the regression analyses and group comparison each) which underlines the
validity of our results [18].Table 1
Group comparison. AR and TD did not differ in age (p¼ 0.98), gender ratio (p¼ 0.99), o
(ACE-R; p ¼ 0.42), Barratt Impulsiveness Scale (BIS; p ¼ 0.87), time of symptom ons
controls (all p > 0.05) regarding age, intracranial volume (ICV), whole brain volume
Controls
n 20
Mean age (SD; range) 66.0
(9.1; 43e85)
Gender ratio: male/female 10/10
Time symptom onset in years (SD)
Uniﬁed Parkinson Disease Rating
Scale (UPDRS)
Subtype ratio
Addenbrooke’s Cognitive
Examination-Revised (ACE-R)
Barratt Impulsiveness Scale (BIS)
L-dopa equivalence units
Whole brain volume in mm3 (SD) 1235.3 (146.2)
Intracranial volume mm3 (SD) 1647.7 (201.5)
Whole brain MT (SD) 0.833 (0.14)
Whole brain R2* (SD) 22.4 (0.9)
**Denotes statistically signiﬁcant difference (p < 0.001).3. Results
3.1. Participants: demographics and whole brain analysis
40 Subjects participated in the study: twenty PD patients (ful-
ﬁlling Queens Square Brain bank criteria [19]) recruited from
neurology clinics and twenty healthy control subjects. None of our
patients had advanced PD with major signs of postural instability
and gait difﬁculty [20], or any diagnosed psychiatric or neurological
disorders other than PD. In particular, exclusion criteria involved
impulse control disorder (ICD), depression (i.e. Beck Depression
Inventory score 21) or cognitive impairments (i.e. Mini-Mental
State Examination score < 25). Impulse control problems were
assessed by the managing neurologist using appropriate ques-
tionnaires [21].
None of the healthy controls reported a history of neurological,
psychiatric or medical disorders or any current medical problems.
All subjects gave written informed consent in accordance with
the approval of the local ethics committee (University College
London, UK).
Motor subtype (i.e. subtype ratio, AR/TD) in PD patients was
deﬁned according to the ratio of UPDRS III tremor score and aki-
netic/rigid score [20]. AR/TD classiﬁcationwas made on the basis of
current signs, with all patients on medication at time of assess-
ment. Nevertheless, there was a high correlation between our
scores [20] and scores as deﬁned by Ref. [22] which is based on
examination ﬁndings and history e and therefore includes symp-
toms reported OFF-state (r ¼ 0.62, p ¼ 0.004). Moreover, none of
our patients were of mixed subtype, which might be more marked
tremor responsive to dopaminergic medications [23].
Note that, for the analysis of our MR-data, the scale by Kang et al.
[20] was chosen as primary scale over others (i.e. Ref. [22]) because
none of our patients showed any major symptoms of postural
instability and gait difﬁculty.
Patients and controls were matched regarding age, gender ratio,
whole brain volume, intracranial volume (ICV) and mean MT and
R2* (all p-values >0.21). In PD-patients, subtype ratio did not
correlate with whole brain volume (t(17) ¼ 0.609, p ¼ 0.551), ICV
(t(17) ¼ 0.772, p ¼ 0.451), or any other measure such as time of
symptom onset or L-dopa equivalent unit (all p’s > 0.18). L-dopa
equivalence units were quantiﬁed as in Ref. [24].
According to Ref. [20] our PD sample comprised 10 AR and 10 TD
patients which differed only in subtype ratio (p < 0.0001), but no
other variables of interest (Table 1). Moreover, AR and TD did notverall scores in UPDRS (p¼ 0.29), Addenbrooke’s Cognitive Examination-Revised
et (p ¼ 0.63) and medication (p ¼ 0.19). AR and TD did not differ from healthy
and gender.
PD patients AR TD
20 10 10
66.25
(9.0; 42e84)
66.3
(5.9; 58e79)
66.2
(11.7; 42e84)
11/9 5/5 6/4
6.27 (4.4) 6.75 (5.0) 5.78 (3.8)
34.6 (17.4) 30.4 (13.2) 38.8 (20.6)
1.1 (0.7) 0.5 (0.2)** 1.7 (0.6)**
88.4 (15.0) 91.3 (7.5) 85.6 (20.1)
0.5 (0.1) 0.5 (0.1) 0.5 (0.1)
393.8 (339.0) 375.4 (268.2) 412.2 (412.2)
1230.4 (102.1) 1193.3 (101.1) 1267.4 (93.5)
1705.1 (140.6) 1678.1 (153.8) 1732.0 (128.4)
0.848 (0.09) 0.835 (0.08) 0.861 (0.09)
22.9 (2.0) 23.1 (2.5) 22.8 (1.6)
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age, gender ratio, etc.; see Table 1, all p > 0.05) and there were no
signiﬁcant outliers in any group.
3.2. Region of interest (ROI) analysis
3.2.1. Substantia nigra (SN)
PD patients exhibited signiﬁcantly smaller SN volumes
(F(1,36) ¼ 9.51, p ¼ 0.004) (Fig. 2A) and lower MT values
(F(1,37) ¼ 7.67, p ¼ 0.009) compared to healthy controls (Fig. 2B).
There were no signiﬁcant differences in R2* (p ¼ 0.09, Fig. 2C).
Further analyses of R2* of the medial and lateral SN also did not
reveal any signiﬁcant group differences (p > 0.05) or interactions
between group and laterality (i.e. group speciﬁc differences in the
medial or lateral part of the SN; p > 0.31). See Table S1 for a
summary.
When relating both MT and R2* of the SN by using regression
analysis (see Methods), we observed a signiﬁcant negative cor-
relation across the whole sample, including controls and PD
patients (F(1,35) ¼ 6.90, p ¼ 0.01). Thus, the lower MT e and, by
inference, reduced structural integrity of the SN e the higher R2*
(i.e. iron).
Importantly, the analysis also revealed a signiﬁcant interaction
with group (F(1,35) ¼ 11,01, p ¼ 0.002) indicating statistically
signiﬁcant differences between healthy controls and PD patients.
Indeed, a signiﬁcant correlation between R2* and MT was found
only in the 20 PD patients (t(17) ¼ 3,34, p ¼ 0.004; Fig. 2E;
Table S2), but not in healthy controls (p ¼ 0.67; Fig. 2D). There
were no other statistically signiﬁcant effects (e.g., with subtype
ratio).
3.2.2. Putamen
Putamen volumes were larger in healthy controls vs. PD patients
(F(1,36) ¼ 5.55, p ¼ 0.02). There were no signiﬁcant differences in
MT (p ¼ 0.35) or R2* (p ¼ 0.7) e see Table S1. However, regression
analysis across all 20 PD patients revealed a signiﬁcant positive
correlation between R2* and subtype ratio (t(17) ¼ 4.342,Fig. 2. Controls had larger SN volumes (A) and higher MT values (B). R2* and MT correlated n
estimates and scatter-plots are based on individual raw data (see Methods).p ¼ 0.0004) (Fig. 3). Thus, the higher the ratio (>1 deﬁnes the TD
group; see above) the greater R2*.
Regression analysis using MTand R2* of the putamen revealed a
signiﬁcant correlation between both measures across the whole
sample (t(37) ¼ 2.78, p ¼ 0.008), which eagain ewas driven by a
signiﬁcant negative correlation between MT and R2* in the 20 PD
patients (t(17) ¼ 2.21, p ¼ 0.04) but not in controls (p ¼ 0.13)
(Table S2).
3.2.3. Caudate
There was no difference in volume (p ¼ 0.33), R2* (p ¼ 0.85)
or MT (p ¼ 0.58) between patients and controls (Table S1).
However, across the 20 PD patients there was a signiﬁcant pos-
itive correlation between R2* and subtype ratio (t(17) ¼ 3.416,
p ¼ 0.003) (Fig. 3). There were no other signiﬁcant effects
(Table S2).
3.2.4. Pallidum
There was no signiﬁcant difference in volume (p ¼ 0.07) or R2*
(p ¼ 0.39) but PD patients exhibited lower MT values than healthy
controls (F(1,37) ¼ 5.004, p ¼ 0.03; Table S1). There were no other
statistically signiﬁcant effects (Table S2).
3.2.5. Thalamus
As for putamen and caudate, there was no signiﬁcant group
effect on volume (p ¼ 0.51), R2* (p ¼ 0.6) or MT (p ¼ 0.17;
Table S1) but a signiﬁcant linear relationship (across the 20 PD
patients) between subtype ratio and R2* (t(16) ¼ 2.197, p ¼ 0.04)
(Fig. 3). There were no other signiﬁcant effects (p > 0.05)
(Table S2).
3.2.6. Nucleus accumbens
There was no signiﬁcant group difference in volume (p ¼ 0.56),
R2* (p ¼ 0.23) or MT (p ¼ 0.46; Table S1) but a positive relation-
ship between subtype ratio and MT (t(17) ¼ 2.27, p ¼ 0.04) across
the 20 PD patients. No other signiﬁcant effects were observed
(p > 0.05).egatively in PD-patients (D) but not controls (C). Bar-plots are based on LME parameter
Fig. 3. R2* and subtype ratio correlations. Within the putamen, caudate and thalamus, but not substantia nigra, ncl. accumbens and pallidum, subtype ratio was positively
correlated with R2*; the greater the tendency towards the TD motor phenotype the higher R2*. Note that the two subjects corresponding to extreme data points in the caudate,
putamen and thalamus did not differ in any dimension other than R2* within these speciﬁc BG structures (i.e. they were no outliers regarding whole brain volume, intracranial
volume, whole brain R2*, whole brain MT, UPDRS, ACE-R, Barratt Impulsiveness Scale, time of symptom onset, age and medication). Thus, they were not excluded from the analyses.
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Taken together, three main patterns emerged:
(1) In PD patients the SN was characterized by reduced volume
and lower MT values (Fig. 2, Table S1),
(2) Within the putamen, caudate and thalamus R2* correlated
positively with subtype ratio (Fig. 3), so the greater the ten-
dency towards the TD motor phenotype the higher R2*
(i.e. iron),
(3) Within the SN and putamen R2* correlated negatively with MT
in PD patients but not in healthy controls (Table S2).
4. Discussion
Our results point towards a functional link between brain iron
accumulation and PD motor symptoms. They show that MRI pa-
rameters can demonstrate differences in the expression of AR and
TD symptoms, and that R2* in some BG structures correlates with
motor phenotype. Therefore, this technique could provide a non-
invasive biomarker to assess trajectories of disease and responses
to treatment in trials, as well as potentially providing mechanistic
insights into the heterogeneity within the PD population.
4.1. R2* and motor subgroup
Our ﬁndings of reduced SN volumes and MT values in PD pa-
tients (Fig. 2) are consistent with previousMRI studies [12,25]. They
correspond well to the known pathophysiology of PD, i.e. neuronal
loss and gliosis [19], and the notion that decreases in SN MT might
reﬂect these structural changes. Although we did not detect any
signiﬁcant correlations with motor symptoms and MT, R2* or vol-
ume, respectively, within the SN, there was a close relationship
between R2* and motor subtype in the putamen, caudate and
thalamus (Fig. 3).Increased R2* within the BG (including SN) and thalamus of PD
patients has been described previously and interpreted as evi-
dence of enhanced iron levels [9]. However, these reports contrast
with ﬁndings of absent changes in nigral iron levels in PD [26,27].
One possibility is that enhanced BG iron levels are not a general
feature of PD but might in fact relate to motor phenotype. Our
results directly support this assumption by showing no overall
differences in R2* between PD patients and healthy controls, but
importantly a signiﬁcant correlation between R2* and subtype
ratio within the putamen, caudate and thalamus. It suggests that
the amount of iron accumulation predicts severity of tremor
dominant symptoms. Conversely, the lower R2*, the more pro-
nounced the akinetic rigid symptoms. Therefore, R2* appears to
be a potential biomarker for motor phenotype in PD which might
help to improve strategies in medical care even in the early stages
of the disease [28].
It might seem surprising that there was no correlation within
the SN between motor phenotype and either volume, R2* or MT.
However, it is possible that SN degeneration is common to all sub-
groups, but factors in other parts of the basal ganglia distinguish
between phenotypes. For example, it has been demonstrated that
AR patients exhibit greater reductions of dopamine in the globus
pallidus [3]. Future post mortem studies might help in establishing
which pathological features are common and different between
motor phenotypes.
4.2. Basal ganglia iron in Parkinson’s disease
Although iron levels seem to be associated with PD [29] the
precise pathophysiological mechanisms are still a matter of debate
[6,27]. One possibility is that imbalanced iron concentration trigger
oxidative stress, which leads to nigral cell loss and subsequently
results in PDmotor symptoms. However, this causative relationship
has been challenged by the view that enhanced iron levels might
only be a secondary phenomenon [30].
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clearly show that the relationship between iron levels (R2*) and
motor symptoms (i.e. subtype ratio) is not a general effect across all
BG structures. Rather, it seems to be predominantly expressed
within the caudate, putamen, and inter-connected thalamus
(Fig. 3). In addition, the effect seems to be iron speciﬁc rather than a
non-speciﬁc degenerative phenomenon because there was no
correlation between subtype ratio and MT (except nucleus
accumbens) in any ROI.
It might perhaps be surprising that increased R2* (i.e. iron load)
is mostmarked in patients with TD rather than AR symptoms, given
the generally worse prognosis in the latter. Patients with pre-
dominant AR phenotype have higher levels of cortical Lewy bodies
[4], consistent with the ﬁnding that this subgroup is more likely to
develop cognitive dysfunction [31]. They also have higher levels of
neuronal loss, gliosis, extra-neuronal melanin deposits and neuro-
axonal dystrophy in the SN [2] and exhibit greater reductions in
dopamine level in the internal globus pallidus [3]. Our ﬁndings
consistently show that enhanced R2* scales with TD symptoms
across several BG structures which is in line with previous animal
studies. In rabbits and monkeys, systemic (intravenous) injections
of iron in the form of dextran lead to increased iron deposits in the
BG, with tremor e not rigidity e as the motor phenotype [7]. Thus,
iron load is likely to be one factor out of many that affect the
phenotype of PD patients [1].
Another differentiating feature between PD patients and
healthy controls lies in the relationship between R2* and MT
(Table S2). In controls, both measures did not correlate in any ROI
which seems to be characteristic for the healthy brain, perhaps
reﬂecting a balanced iron homeostasis [6]. In PD patients, on the
other hand, iron content (R2*) varied negatively as a function of
structural integrity (MT) within the SN and putamen (Table S2).
This pattern conforms to the notion that enhanced iron levels relate
to neurodegeneration and motor symptoms of PD [6].
Finally, it should be noted that our results are not based on a
direct comparison between AR vs. TD subgroups but regression
analyses including all 20 PD patients and their AR/TD subtype ratio.
This approach rests on the notion that TD and AR subtypes reﬂect
different points on a continuum. Indeed, some patients who
initially present with one motor phenotype can later develop fea-
tures of the other (albeit predominantly from TD to AR, rather than
the reverse) [32] which argues against AR and TD being two
discrete entities.
4.3. Conclusion
Overall, our ﬁndings suggest that AR and TDmotor symptoms of
PD directly relate to R2* within speciﬁc BG structures and thalamus.
This result is important because emerging evidence suggests that
patients with predominant AR phenotype are more likely to
develop cognitive impairment, falls, sleep disorders and autonomic
impairment. If R2* is indeed a good marker of iron load, this points
to an important pathophysiological marker to distinguish between
motor phenotypes, and hence disease prognosis.
Competing interests
None.
Funding
This work was supported by the Wellcome Trust and NIHR BRC
at UCL/UCLH and the Hamburg state cluster of excellence
(neurodapt!).Acknowledgments
Wewould like to thank Dr. Bogdan Draganski for support in data
acquisition and helpful comments on a previous version of the
manuscript.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.parkreldis.2013.08.011.References
[1] Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH,
Rodriguez M, et al. Missing pieces in the Parkinson’s disease puzzle. Nat Med
2010;16:653e61.
[2] Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups
of Parkinson’s disease. J Neuropathol Exp Neurol 1991;50:743e55.
[3] Rajput AH, Sitte HH, Rajput A, Fenton ME, Piﬂ C, Hornykiewicz O. Globus
pallidus dopamine and Parkinson motor subtypes: clinical and brain
biochemical correlation. Neurology 2008;70:1403e10.
[4] Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ.
A clinico-pathological study of subtypes in Parkinson’s disease. Brain
2009;132:2947e57.
[5] Antonini A, Vontobel P, Psylla M, Gunther I, Maguire PR, Missimer J,
et al. Complementary positron emission tomographic studies of the
striatal dopaminergic system in Parkinson’s disease. Arch Neurol
1995;52:1183e90.
[6] Sian-Hülsmann J, Mandel S, Youdim MBH, Riederer P. The relevance of iron in
the pathogenesis of Parkinson’s disease. J Neurochem 2011;118:939e57.
[7] Oberhauser E, Weinstein V, Asenjo A. Iron concentration bal ganglia and ce-
rebral cortex obtained by overloading rabbits and monkeys with iron dextran.
J Neurosurg 1970;32:677e9.
[8] Draganski B, Ashburner J, Hutton C, Kherif F, Frackowiak RSJ, Helms G,
et al. Regional speciﬁcity of MRI contrast parameter changes in normal
ageing revealed by voxel-based quantiﬁcation (VBQ). Neuroimage
2011;55:1423e34.
[9] Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, et al. Magnetic
resonance imaging markers of Parkinson’s disease nigrostriatal signature.
Brain 2010;133:3423e33.
[10] Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson dis-
ease: a potential biomarker of disease status. Neurology 2008;70:1411e7.
[11] Wolff SD, Balaban RS. Magnetization transfer contrast (MTC) and tissue water
proton relaxation in vivo. Magn Reson Med 1989;10:135e44.
[12] Eckert T, Sailer M, Kaufmann J, Schrader C, Peschel T, Bodammer N, et al.
Differentiation of idiopathic Parkinson’s disease, multiple system atrophy,
progressive supranuclear palsy, and healthy controls using magnetization
transfer imaging. Neuroimage 2004;21:229e35.
[13] Bunzeck N, Schütze H, Stallforth S, Kaufmann J, Düzel S, Heinze H-J, et al.
Mesolimbic novelty processing in older adults. Cereb Cortex 2007;17:
2940e8.
[14] Fasano M, Bergamasco B, Lopiano L. Modiﬁcations of the iron-neuromelanin
system in Parkinson’s disease. J Neurochem 2006;96:909e16.
[15] Helms G, Draganski B, Frackowiak R, Ashburner J, Weiskopf N. Improved
segmentation of deep brain grey matter structures using magnetization
transfer (MT) parameter maps. Neuroimage 2009;47:194e8.
[16] Han X, Jovicich J, Salat D, van der Kouwe A, Quinn B, Czanner S, et al. Reli-
ability of MRI-derived measurements of human cerebral cortical thickness:
the effects of ﬁeld strength, scanner upgrade and manufacturer. Neuroimage
2006;32:180e94.
[17] Leach LF, Henson RK. The use and impact of adjusted R2 effects in published
regression research. Mult Linear Regres Viewp 2007;33:1e11.
[18] Rothman KJ. No adjustments are needed for multiple comparisons. Epide-
miology 1990;1:43e6.
[19] Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100
cases of Parkinson’s disease. Arch Neurol 1993;50:140e8.
[20] Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical
characteristics in early Parkinson’s disease in a central California population-
based study. Mov Disord 2005;20:1133e42.
[21] Christenson GA, Faber RJ, de Zwaan M, Raymond NC, Specker SM, Ekern MD,
et al. Compulsive buying: descriptive characteristics and psychiatric comor-
bidity. J Clin Psychiatry 1994;55:5e11.
[22] Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol
2001;58:1611e5.
[23] Sung YH, Chung SJ, Kim SR, Lee MC. Factors predicting response to dopami-
nergic treatment for resting tremor of Parkinson’s disease. Mov Disord
2008;23:137e40.
[24] Evans AH, Katzenschlager R, Paviour D, O’Sullivan JD, Appel S, Lawrence AD,
et al. Punding in Parkinson’s disease: its relation to the dopamine dysregu-
lation syndrome. Mov Disord 2004;19:397e405.
N. Bunzeck et al. / Parkinsonism and Related Disorders 19 (2013) 1136e11421142[25] Seppi K, Schocke MF. An update on conventional and advanced magnetic
resonance imaging techniques in the differential diagnosis of neurodegener-
ative parkinsonism. Curr Opin Neurol 2005;18:370e5.
[26] Loefﬂer DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, et al.
Transferrin and iron in normal, Alzheimer’s disease, and Parkinson’s disease
brain regions. J Neurochem 1995;65:710e24.
[27] Friedman A, Galazka-Friedman J, Koziorowski D. Iron as a cause of Parkinson
disease e a myth or a well established hypothesis? Parkinsonism Relat Disord
2009;15(Suppl. 3):S212e4.
[28] Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-
Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Prog Neurobiol 2010;92:330e44.[29] Lv Z, Jiang H, Xu H, Song N, Xie J. Increased iron levels correlate with the
selective nigral dopaminergic neuron degeneration in Parkinson’s disease.
J Neural Transm 2011;118:361e9.
[30] Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in
the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci 2004;1012:193e208.
[31] Burn DJ, Rowan EN, Allan LM, Molloy S, O’Brien JT, McKeith IG. Motor subtype
and cognitive decline in Parkinson’s disease, Parkinson’s disease with de-
mentia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry
2006;77:585e9.
[32] Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in
motor subtype and risk for incident dementia in Parkinson’s disease.
Mov Disord 2006;21:1123e30.
